Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 17 Feb 2005 FDA grants priority review to levetiracetam for use in childhood epilepsy Read More 7 Feb 2005 UCB Group preliminary full-year 2004 results Read More 25 Jan 2005 UCB Pharma enters into agreement to collaborate on two Biotherapeutic Inflammation Programs with Millennium Read More 19 Jan 2005 UCB Confirms Annual Zyrtec Sales In The US - Xyzal Sells More Than Zyrtec In Europe Read More 23 Dec 2004 Xyzal®* Is The First And Only Antihistamine Licensed For Persistent Allergic Rhinitis Read More 17 Dec 2004 UCB: research budget for 2005 up significantly after conversion to biopharmaceutics Read More Pagination First page Previous page Previous … Page 183 Page 184 Page 185 Page 186 Current page 187 Page 188 Page 189 Page 190 Page 191 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
